Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Real World Outcomes of Liposomal Daunorubicin and Cytarabine Versus 7+3 in Patients with Secondary Acute Myeloid Leukemia

Ellen Madarang, PharmD, Jillian Lykon, PharmD, Nina Nguyen, MD, Justin M. Watts, MD, Terrence J Bradley, MD, Namrata S Chandhok, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142595

Published: 2020

Journal Articles

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin M. Watts, MD, Tara Lin, MD, Eunice S. Wang, MD, Alice S. Mims, MD, Elizabeth H. Cull, MD, Prapti A. Patel, MD, Paul J. Shami, MD, Roland B. Walter, MDPhDMS, Christopher R. Cogle, Ruth A. Chenault, MS, Bret Macpherson, MSc, MBA, Allison Given Chunyk, Catherine J. McMahan, Jane A. Gross, PhD, Scott Stromatt, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141619

Published: 2020

Journal Articles

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Sung Choe, PhD, Hongfang Wang, PhD, Gail J. Roboz, MD, Courtney D. DiNardo, MD MSCE, Eytan M. Stein, MD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Justin M. Watts, MD, Bin Fan, PhD, Parham Nejad, BSc, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD, Richard M. Stone, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136589

Published: 2020

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Venkata Thammineni, MD, Terrence J Bradley, MD, Felipe Novoa, NP, Deukwoo Kwon, Justin M. Watts, MD

Blood (2019) 134 (Supplement_1): 5107.

https://doi.org/10.1182/blood-2019-131006

Published: 2019

Journal Articles

Evaluation of Minnelide As a Potential Therapeutic Agent for Preventing the Relapse of AML

Pooja Roy, MBBS, Bhuwan Giri, MD, Vanessa Tonin Garrido, PhD, Dujon Brandon Edwards, Justin M. Watts, MD, Sulagna Banerjee, PhD, Vikas Dudeja, PhD, Sundaram Ramakrishnan, PhD, Ashok Saluja, PhD

Blood (2019) 134 (Supplement_1): 5159.

https://doi.org/10.1182/blood-2019-123567

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Justin M. Watts, MD, Terrence J Bradley, MD, Amber Thomassen, Andrew M. Brunner, MD, Mark D. Minden, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Sameem Abedin, MD, Amanda J Baines, Olena Barbash, PhD, Shelby Gorman, Brandon E Kremer, MD PhD, Gautam M. Borthakur, MD

Blood (2019) 134 (Supplement_1): 2656.

https://doi.org/10.1182/blood-2019-130337

Published: 2019

Journal Articles

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Tim H Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Camille Abboud, MD, Justin M. Watts, MD, Gianantonio Rosti, MD, Alexander Russell-Smith, Andrea Viqueira, MD, Arlene Reisman, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 4157.

https://doi.org/10.1182/blood-2019-124344

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Justin M Watts, MD, Terrence J Bradley, MD, Amber Thomassen, MA, MSN, Yvonne Trang Dinh, BS, Dalissa Tejera, MSN, Kristen Englund, Sorab Boga, MPH, Randy Astaiza, BS, Charles J Chen, MPH, Malika Abdur-Rahman, BS, MSED, Marinescu Ion, CCRC, FMG, Aymee Perez, PhD, Masoumeh Tayari, PhD, Lluis Morey, PhD, Maria E. Figueroa, MD, Ramin Shiekhattar, PhD, Arthur Zelent, PhD, Ronan Swords, MD PhD

Blood (2018) 132 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2018-99-115411

Published: 2018

Journal Articles

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Blood (2018) 132 (Supplement 1): 688.

https://doi.org/10.1182/blood-2018-99-110381

Published: 2018

Journal Articles

An Enhanced Sensitivity DNA Sequencing Protocol for the Detection in AML of Measurable Residual Disease (MRD) Applicable for All Mutations

Hugh Y. Rienhoff, Jr., MD, Georges Natsoulis, PhD, Amber Jones, MA, Jennifer Peppe, BS, Ru Cao, PhD, Khalid Hanif, PhD, Justin M. Watts, MD

Blood (2018) 132 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2018-99-115505

Published: 2018

Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Blood (2018) 132 (Supplement 1): 561.

https://doi.org/10.1182/blood-2018-99-110595

Published: 2018

Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Blood (2018) 132 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2018-99-111264

Published: 2018

NARROW

Real World Outcomes of Liposomal Daunorubicin and Cytarabine Versus 7+3 in Patients with Secondary Acute Myeloid Leukemia

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Evaluation of Minnelide As a Potential Therapeutic Agent for Preventing the Relapse of AML

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

An Enhanced Sensitivity DNA Sequencing Protocol for the Detection in AML of Measurable Residual Disease (MRD) Applicable for All Mutations

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only